Connection

GREG CUNY to Models, Molecular

This is a "connection" page, showing publications GREG CUNY has written about Models, Molecular.
Connection Strength

0.765
  1. Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2713-9.
    View in: PubMed
    Score: 0.096
  2. Synthesis, in vitro evaluation and cocrystal structure of 4-oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase (CpIMPDH) inhibitors. J Med Chem. 2014 Dec 26; 57(24):10544-50.
    View in: PubMed
    Score: 0.093
  3. Optimization of tricyclic Nec-3 necroptosis inhibitors for in vitro liver microsomal stability. Bioorg Med Chem Lett. 2012 Sep 01; 22(17):5685-8.
    View in: PubMed
    Score: 0.079
  4. Synthesis of tetracyclic indoles via intramolecular a-arylation of ketones. J Org Chem. 2012 Apr 20; 77(8):4123-30.
    View in: PubMed
    Score: 0.078
  5. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. Bioorg Med Chem Lett. 2012 Mar 01; 22(5):2015-9.
    View in: PubMed
    Score: 0.077
  6. Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors. Bioorg Med Chem Lett. 2011 Apr 01; 21(7):2098-101.
    View in: PubMed
    Score: 0.072
  7. Role of the Mobile Active Site Flap in IMP Dehydrogenase Inhibitor Binding. ACS Infect Dis. 2025 Feb 14; 11(2):442-452.
    View in: PubMed
    Score: 0.047
  8. Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents. J Med Chem. 2018 06 14; 61(11):4739-4756.
    View in: PubMed
    Score: 0.030
  9. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors. Chem Biol. 2015 Sep 17; 22(9):1174-84.
    View in: PubMed
    Score: 0.025
  10. A new class of small molecule inhibitor of BMP signaling. PLoS One. 2013; 8(4):e62721.
    View in: PubMed
    Score: 0.021
  11. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. Biochemistry. 2013 Mar 12; 52(10):1725-36.
    View in: PubMed
    Score: 0.021
  12. Fluorescence polarization assay for inhibitors of the kinase domain of receptor interacting protein 1. Anal Biochem. 2012 Aug 15; 427(2):164-74.
    View in: PubMed
    Score: 0.020
  13. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. Antiviral Res. 2012 Apr; 94(1):18-24.
    View in: PubMed
    Score: 0.019
  14. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry. 2011 Nov 01; 50(43):9399-408.
    View in: PubMed
    Score: 0.019
  15. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One. 2010 May 07; 5(5):e10504.
    View in: PubMed
    Score: 0.017
  16. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010 Apr 08; 53(7):2709-18.
    View in: PubMed
    Score: 0.017
  17. The structural basis of Cryptosporidium -specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc. 2010 Feb 03; 132(4):1230-1.
    View in: PubMed
    Score: 0.017
  18. Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol. 2006 Apr 01; 176(7):4208-20.
    View in: PubMed
    Score: 0.013
  19. Ring opening cross-metathesis on solid support: a combinatorial library synthesis of highly functionalized cyclopentanes. Mol Divers. 1997-1998; 3(3):173-9.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.